Po-01-206 molecular modeling of clinical kcnj2 mutations reveals structure-function impact on pip2 binding site

Binding phosphatidylinositol 4,5-bisphosphate (PIP2) is essential for Kir2.1(encoded by KCNJ2), function. Disease associated KCNJ2 mutations, such as those associated with Andersen-Tawil Syndrome (ATS), may exert molecular dysfunction by interrupting PIP2 binding, however a full-length molecular model of Kir2.1 has not been developed to explore this hypothesis. Elucidate the molecular structure of Kir2.1 and determine the functional impact of clinical KCNJ2 mutations on PIP2 binding using experimental and improved molecular dynamic (MD) method. Whole-cell patch clamp experiments of WT-Kir2.1 and selected mutations were performed on stably transfected HEK293 cells using a standard protocol. A full-length Kir2.1 tetramer model (open and closed conformational states) based on Kir2.2 cryo-EM structure using MOE was created. Mutations (R67Q, G300D, R218L) were individually introduced to the channel, and a mutagenesis analysis was performed. Initially, MD simulation for 100ns was performed for wild-type (WT) and mutated structures (GROMACS software). We expanded the model to include +/- bound PIP2. Due to > 77% degree of homology of Kir2.2 (6m84) with Kir2.1, we developed a MD protocol with Kir2.2 as test system. The 2.5% free PIP2 molecules were released into the membrane and MD simulation was performed for 700ns using Amber software. Homomeric WT demonstrated normal Kir2.1 function while mutations G300D, R67Q, and R218L showed complete loss of function. Mutational analysis revealed that residue changes result in disruption of hydrogen bonding and affects the structural conformation at the residue sight and caused fluctuation of residues in other regions, i.e., selectivity filter and pore domain. The improved MD protocol validated Kir2.2 PIP2 binding sites. Moreover, we found mutation disruption of hydrogen bonds and hydrophobic interaction analysis between the channel and PIP2 molecules revealed significant structural changes. We developed the first full length MD model of Kir2.1 and found that ATS KCNJ2 mutations disrupt normal conformation and hydrogen bonding. Further, we validated PIP2 binding sites which illustrate the robustness of our method, and this technique can be applied to delineate Kir2.1 molecular PIP2 binding sites. Combined with experimental validation, our modeling will increase our understanding of structure-function relationships of KCNJ2 clinical mutations.